Press Enter to search · Esc to close
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
A new wave of reviews argues that aging biology — not individual diseases — is medicine's highest-leverage target. Heart failure may be the proving ground.
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.
A new perspective in Aging Cell argues that the body's capacity to buffer immune decline — not the disease markers we obsess over — may be the truer measure of how well we age.
Two new reviews argue your gut bugs are one of the most workable levers on healthy aging — and the plants on your plate are how you nudge them.
A small Duke pilot is reuniting people from a 15-year-old exercise trial to ask a question longevity culture keeps dodging: does the same workout still work as we age?
A new French trial is testing whether decades of exercise preserve a unified signature of biological youth — and population data on diabetes mortality suggests the stakes are higher than we thought.
Transcriptomic clocks are joining PhenoAge and GrimAge in a fast-maturing toolkit — and early longitudinal work hints that ordinary medications may nudge the dial.
The same peptide class everyone's whispering about in the locker room is showing up in neurology, nephrology, and orthopedic data. The signal looks real — but moderate, not miraculous.